Tigilanol tiglate in veterinary oncology

Tigilanol tiglate, branded as STELFONTA®, is approved and marketed as a veterinary pharmaceutical for treatment of non-metastatic, unresectable canine mast cell tumours1 in the European Union, Switzerland and the United Kindgom. Tigilanol tiglate canine.

STELFONTA® is marketed and distributed in these juridictions through a partnership with Virbac, a global animal health company.

STELFONTA® is also under late-stage review for treatment of canine mast cell tumours by the US Food and Drug Administration's Center for Veterinary Medicines (FDA-CVM) and the Australian Pesticides and Veterinary Medicines Authority (APVMA).

Tiglianol tiglate was efficacious and well-tolerated in a randomised clinical trial

In a multicentre, randomised, blinded and controlled field efficacy study in the USA conducted in 123 dogs, a single intratumoural injection of tigilanol tiglate resulted in complete resolution (Complete Response) of the treated mast cell tumours in 75% of patients1 (see figure below).  For dogs that did not fully respond, a second tigilanol tiglate treatment increased the Complete Response rate to 88%, with no local tumour recurrence in 93% in dogs at 84 days post treatment2 and no recurrence in 89% of evaluable cases at 12 months post treatment.

Importantly, tigilanol tiglate was very well tolerated and animals had a good quality of life during and after treatment2.

Further clinical trials are in progress in Australia, the USA, Europe and the UK to determine efficacy of tigilanol tiglate in additional indications in dogs and horses.

Field efficacy trial results following a single treatment with tigilanol tiglate (STELFONTA®)

chart

Typical progression of clinical response following intratumoural administration of tigilanol tiglate into a canine mast cell tumour

case studiesDiscover tigilanol tiglate case studies

 


  1. European Medicines Agency. (2020).STELFONTA®.
  2. De Ridder et al. (2020). Journal of Veterinary Internal Medicine, 2020, 1-15.